389 related articles for article (PubMed ID: 30092812)
1. EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry.
Mraihi Z; Ben Amar J; Bouacha H; Rammeh S; Hila L
BMC Pulm Med; 2018 Aug; 18(1):132. PubMed ID: 30092812
[TBL] [Abstract][Full Text] [Related]
2. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
[TBL] [Abstract][Full Text] [Related]
3. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
[TBL] [Abstract][Full Text] [Related]
4. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
Wu SG; Chang YL; Lin JW; Wu CT; Chen HY; Tsai MF; Lee YC; Yu CJ; Shih JY
PLoS One; 2011; 6(8):e23303. PubMed ID: 21858063
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer.
Ling Y; Yang X; Li W; Li Z; Yang L; Qiu T; Guo L; Dong L; Li L; Ying J; Lin D
Oncotarget; 2016 Aug; 7(33):52862-52869. PubMed ID: 27418143
[TBL] [Abstract][Full Text] [Related]
6. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
[TBL] [Abstract][Full Text] [Related]
8. A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.
Wang X; Wang G; Hao Y; Xu Y; Zhang L
Int J Clin Exp Pathol; 2014; 7(7):4310-6. PubMed ID: 25120814
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study.
Jain D; Iqbal S; Walia R; Malik P; Cyriac S; Mathur SR; Sharma MC; Madan K; Mohan A; Bhalla A; Pathy S; Kumar L; Guleria R
Indian J Med Res; 2016 Mar; 143(3):308-14. PubMed ID: 27241644
[TBL] [Abstract][Full Text] [Related]
10. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
11. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies.
Ho HL; Kao HL; Yeh YC; Chou TY
Diagn Pathol; 2019 Jun; 14(1):59. PubMed ID: 31221183
[TBL] [Abstract][Full Text] [Related]
12. Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma.
Abdelmaksoud-Dammak R; Ammous-Boukhris N; Saadallah-Kallel A; Charfi S; Khemiri S; Khemakhem R; Kallel N; Ben Kridis-Rejeb W; Sallemi-Boudawara T; Khanfir A; Yangui I; Daoud J; Mokdad-Gargouri R
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011410
[TBL] [Abstract][Full Text] [Related]
13. Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.
Kim CH; Kim SH; Park SY; Yoo J; Kim SK; Kim HK
Cancer Res Treat; 2015 Oct; 47(4):653-60. PubMed ID: 25687872
[TBL] [Abstract][Full Text] [Related]
14. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY
Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325
[TBL] [Abstract][Full Text] [Related]
15. Detection of Epidermal Growth Factor Receptor (EGFR) Gene Mutation in Formalin Fixed Paraffin Embedded Tissue by Polymerase Chain Reaction-Single Strand Conformational Polymorphism (PCR-SSCP) in Non-Small Cell Lung Cancer in the Northeastern Region of Thailand.
Saiyaros K; Kritpetcharat P; Pairojkul C; Sithithaworn J
Asian Pac J Cancer Prev; 2019 May; 20(5):1339-1343. PubMed ID: 31127887
[TBL] [Abstract][Full Text] [Related]
16. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
Tsai TH; Wu SG; Chang YL; Wu CT; Tsai MF; Wei PF; Yang CH; Yu CJ; Yang PC; Shih JY
J Thorac Oncol; 2012 Jun; 7(6):993-1000. PubMed ID: 22525557
[TBL] [Abstract][Full Text] [Related]
17. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
[TBL] [Abstract][Full Text] [Related]
18. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.
Kozu Y; Tsuta K; Kohno T; Sekine I; Yoshida A; Watanabe S; Tamura T; Yokota J; Suzuki K; Asamura H; Furuta K; Tsuda H
Lung Cancer; 2011 Jul; 73(1):45-50. PubMed ID: 21129809
[TBL] [Abstract][Full Text] [Related]
19. EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer.
Houang M; Sioson L; Clarkson A; Watson N; Farzin M; Toon CW; Raut A; O'Toole SA; Cooper WA; Pavlakis N; Mead S; Chou A; Gill AJ
Pathology; 2014 Oct; 46(6):501-8. PubMed ID: 25158821
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry for EGFR Mutation Detection in Non-Small-Cell Lung Cancer.
Hitij NT; Kern I; Sadikov A; Knez L; Stanič K; Zwitter M; Cufer T
Clin Lung Cancer; 2017 May; 18(3):e187-e196. PubMed ID: 28089159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
